Canada · Delayed Price · Currency is CAD NeuPath Health Statistics
Total Valuation
NeuPath Health has a market cap or net worth of CAD 32.48 million. The enterprise value is 42.61 million.
| Market Cap | 32.48M |
| Enterprise Value | 42.61M |
Important Dates
The last earnings date was Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuPath Health has 56.98 million shares outstanding. The number of shares has increased by 6.31% in one year.
| Current Share Class | 56.98M |
| Shares Outstanding | 56.98M |
| Shares Change (YoY) | +6.31% |
| Shares Change (QoQ) | +1.66% |
| Owned by Insiders (%) | 5.35% |
| Owned by Institutions (%) | 10.83% |
| Float | 49.08M |
Valuation Ratios
The trailing PE ratio is 24.87 and the forward PE ratio is 6.19.
| PE Ratio | 24.87 |
| Forward PE | 6.19 |
| PS Ratio | 0.37 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 18.98 |
| P/FCF Ratio | 13.48 |
| P/OCF Ratio | 9.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.20, with an EV/FCF ratio of 17.68.
| EV / Earnings | 31.73 |
| EV / Sales | 0.48 |
| EV / EBITDA | 9.20 |
| EV / EBIT | 17.85 |
| EV / FCF | 17.68 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.19 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 2.84 |
| Debt / FCF | 5.46 |
| Interest Coverage | 3.04 |
Financial Efficiency
Return on equity (ROE) is 7.24% and return on invested capital (ROIC) is 7.47%.
| Return on Equity (ROE) | 7.24% |
| Return on Assets (ROA) | 3.30% |
| Return on Invested Capital (ROIC) | 7.47% |
| Return on Capital Employed (ROCE) | 6.89% |
| Weighted Average Cost of Capital (WACC) | 8.58% |
| Revenue Per Employee | 585,342 |
| Profits Per Employee | 8,836 |
| Employee Count | 152 |
| Asset Turnover | 1.97 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -702,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +107.27% in the last 52 weeks. The beta is 1.07, so NeuPath Health's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +107.27% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 0.53 |
| Relative Strength Index (RSI) | 39.06 |
| Average Volume (20 Days) | 65,459 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeuPath Health had revenue of CAD 88.97 million and earned 1.34 million in profits. Earnings per share was 0.02.
| Revenue | 88.97M |
| Gross Profit | 16.64M |
| Operating Income | 2.39M |
| Pretax Income | 926,000 |
| Net Income | 1.34M |
| EBITDA | 3.35M |
| EBIT | 2.39M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 3.51 million in cash and 13.16 million in debt, with a net cash position of -9.65 million or -0.17 per share.
| Cash & Cash Equivalents | 3.51M |
| Total Debt | 13.16M |
| Net Cash | -9.65M |
| Net Cash Per Share | -0.17 |
| Equity (Book Value) | 23.43M |
| Book Value Per Share | 0.40 |
| Working Capital | 2.25M |
Cash Flow
In the last 12 months, operating cash flow was 3.41 million and capital expenditures -996,000, giving a free cash flow of 2.41 million.
| Operating Cash Flow | 3.41M |
| Capital Expenditures | -996,000 |
| Depreciation & Amortization | 961,000 |
| Net Borrowing | -2.24M |
| Free Cash Flow | 2.41M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 18.70%, with operating and profit margins of 2.68% and 1.51%.
| Gross Margin | 18.70% |
| Operating Margin | 2.68% |
| Pretax Margin | 1.04% |
| Profit Margin | 1.51% |
| EBITDA Margin | 3.76% |
| EBIT Margin | 2.68% |
| FCF Margin | 2.71% |
Dividends & Yields
NeuPath Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.31% |
| Shareholder Yield | -6.31% |
| Earnings Yield | 4.14% |
| FCF Yield | 7.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NeuPath Health is 0.77, which is 35.09% higher than the current price. The consensus rating is "Buy".
| Price Target | 0.77 |
| Price Target Difference | 35.09% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuPath Health has an Altman Z-Score of 2.01 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 6 |